Plato Investment Management Ltd Takes $38,000 Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Plato Investment Management Ltd acquired a new stake in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) during the first quarter, according to its most recent filing with the SEC. The fund acquired 4,119 shares of the company’s stock, valued at approximately $38,000.

Other institutional investors have also added to or reduced their stakes in the company. Virtus Investment Advisers Inc. bought a new position in Voyager Therapeutics in the 1st quarter valued at $118,000. Price T Rowe Associates Inc. MD grew its position in Voyager Therapeutics by 3.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,041,930 shares of the company’s stock worth $9,702,000 after buying an additional 37,144 shares in the last quarter. Lazard Asset Management LLC increased its stake in Voyager Therapeutics by 95.3% in the 1st quarter. Lazard Asset Management LLC now owns 18,742 shares of the company’s stock worth $174,000 after acquiring an additional 9,146 shares during the last quarter. American International Group Inc. raised its holdings in shares of Voyager Therapeutics by 22.9% in the 1st quarter. American International Group Inc. now owns 19,397 shares of the company’s stock valued at $181,000 after acquiring an additional 3,610 shares in the last quarter. Finally, Ameritas Investment Partners Inc. boosted its position in shares of Voyager Therapeutics by 49.6% during the 1st quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company’s stock valued at $37,000 after acquiring an additional 1,300 shares during the last quarter. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Stock Performance

Shares of VYGR stock traded down $0.51 on Thursday, hitting $8.68. 303,144 shares of the company’s stock traded hands, compared to its average volume of 692,791. The stock has a market capitalization of $472.11 million, a price-to-earnings ratio of -173.37 and a beta of 0.96. The company’s fifty day simple moving average is $8.38 and its 200 day simple moving average is $8.38. Voyager Therapeutics, Inc. has a one year low of $6.06 and a one year high of $11.72.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Monday, May 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.24. Voyager Therapeutics had a negative return on equity of 1.28% and a negative net margin of 2.56%. The firm had revenue of $19.52 million for the quarter, compared to analysts’ expectations of $10.33 million. As a group, sell-side analysts anticipate that Voyager Therapeutics, Inc. will post -1.39 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on VYGR shares. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research report on Wednesday. Wedbush lowered their price objective on shares of Voyager Therapeutics from $10.00 to $8.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 14th. Oppenheimer reaffirmed an “outperform” rating and set a $18.00 price objective on shares of Voyager Therapeutics in a report on Wednesday, May 15th. Finally, StockNews.com cut Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, May 13th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, Voyager Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $18.00.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.